{"id": "372776", "url": "https://fevir.net/resources/Composition/372776", "date": "2025-09-02T18:37:30.919Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence-report-expanded"], "versionId": "34", "lastUpdated": "2025-09-02T18:37:30.919Z"}, "type": {"text": "Comparative Evidence Report", "coding": [{"code": "ComparativeEvidenceReport", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ComparativeEvidenceReport"}]}, "title": "Comparative Evidence Report for QUARTET USA Trial", "author": [{"display": "Joanne Dehnbostel"}], "status": "final", "custodian": {"type": "Organization", "display": "Computable Publishing LLC", "reference": "Organization/118079"}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-description", "valueMarkdown": "This is an example of a Comparative Evidence Report describing the QUARTET USA Randomized Controlled Trial for the EBM on FHIR Implementation Guide."}], "relatesTo": [{"type": "cite-as", "targetMarkdown": "Comparative Evidence Report for QUARTET USA Trial [Database Entry: FHIR Composition Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 372776. Revised 2025-09-02. Available at: https://fevir.net/resources/Composition/372776. Computable resource at: https://fevir.net/resources/Composition/372776."}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "372776", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Composition", "section": [{"code": {"coding": [{"code": "introduction", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Introduction"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">New approaches are needed to lower blood pressure (BP) given persistently low control rates. QUARTET USA sought to evaluate the effect of four-drug, quarter-dose BP lowering combination in patients with hypertension.</span></p></div>", "status": "additional"}, "title": "Introduction Section"}, {"code": {"coding": [{"code": "study-sample", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Study Sample"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Group", "display": "Enrolled Group for QUARTET USA Trial", "reference": "Group/372797"}], "title": "Study Sample", "section": [{"code": {"coding": [{"code": "eligibility-criteria", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Eligibility Criteria"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Group", "display": "Eligibility Criteria for QUARTET USA Trial", "reference": "Group/372778"}], "title": "Eligibility Criteria"}]}, {"code": {"coding": [{"code": "intervention-group", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Intervention Group"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Group", "display": "QUARTET USA Trial Quadpill group", "reference": "Group/375175"}], "title": "Intervention Group", "section": [{"code": {"coding": [{"code": "intervention-description", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Intervention Description"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "ActivityDefinition", "display": "Quadpill once daily", "reference": "ActivityDefinition/375159"}], "title": "Intervention Description"}]}, {"code": {"coding": [{"code": "comparator-group", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Comparator Group"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Group", "display": "QUARTET USA Trial Control Group", "reference": "Group/375182"}], "title": "Comparator Group", "section": [{"code": {"coding": [{"code": "comparator-description", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Comparator Description"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "ActivityDefinition", "display": "Candesartan 8 mg once daily", "reference": "ActivityDefinition/375181"}], "title": "Comparator Description"}, {"code": {"coding": [{"code": "GroupAssignment", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "GroupAssignment"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "EvidenceVariable", "display": "GroupAssignment: Quadpill vs. Candesartan", "reference": "EvidenceVariable/375183"}], "title": "Group Assignment (EvidenceVariable)"}]}, {"code": {"coding": [{"code": "research-study", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Research Study"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">Trial registration number: </span><a href=\"http://clinicaltrials.gov/show/NCT03640312\" title=\"See in ClinicalTrials.gov\" style=\"box-sizing: inherit; background-color: rgb(255, 255, 255); color: rgb(0, 113, 188); text-decoration: none; font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal;\">NCT03640312</a><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">.</span></p></div>", "status": "additional"}, "entry": [{"type": "ResearchStudy", "display": "Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension", "reference": "ResearchStudy/367879"}], "title": "Research Study"}, {"code": {"coding": [{"code": "methods", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Methods"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">QUARTET USA was a randomized (1:1), double-blinded trial conducted in federally qualified health centers among adults with hypertension. Participants received either a quadpill of candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg or candesartan 8 mg for 12 weeks. If BP was &gt;130/&gt;80 mm Hg at 6 weeks in either arm, then participants received open label add-on amlodipine 5 mg. </span></p><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">The primary outcome was mean change in systolic blood pressure (SBP) at 12 weeks, controlling for baseline BP. Secondary outcomes included mean change in diastolic blood pressure (DBP), and safety included serious adverse events, relevant adverse drug effects, and electrolyte abnormalities. </span></p></div>", "status": "additional"}, "title": "Methods Section"}, {"code": {"coding": [{"code": "baseline-characteristics", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Baseline Characteristics"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">Among 62 participants randomized between August 2019-May 2022 (n = 32 intervention, n = 30 control), mean (SD) age was 52 (11.5) years, 45% were female, 73% identified as Hispanic, and 18% identified as Black. Baseline mean (SD) SBP was 138.1 (11.2) mmHg, and baseline mean (SD) DBP was 84.3 (10.5) mmHg. </span></p></div>", "status": "additional"}, "entry": [{"type": "Composition", "display": "Baseline Characteristics Report for QUARTET Trial", "reference": "Composition/370510"}], "title": "Baseline Characteristics"}, {"code": {"text": "Participant Flow", "coding": [{"code": "participant-flow", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Participant Flow"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Composition", "display": "Participant Flow Report for QUARTET USA Trial", "reference": "Composition/370512"}], "title": "Participant Flow"}, {"code": {"coding": [{"code": "outcome-measures", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measures"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "List", "display": "Outcome Measure List for QUARTET USA Trial", "reference": "List/375184"}], "title": "Outcome Variables"}, {"code": {"coding": [{"code": "outcome-findings", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Findings"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">In a modified intention-to-treat analysis, there was no significant difference in SBP (-4.8 mm Hg [95% CI: -10.8, 1.3, p = 0.123] and a -4.9 mmHg (95% CI: -8.6, -1.3, p = 0.009) greater mean DBP change in the intervention arm compared with the control arm at 12 weeks. Adverse events did not differ significantly between arms. The quadpill had a similar SBP and greater DBP lowering effect compared with candesartan 8 mg. </span></p></div>", "status": "additional"}, "entry": [{"type": "Composition", "display": "Outcome Measure Report for QUARTET USA Trial", "reference": "Composition/375280"}], "title": "Outcome Findings"}, {"code": {"coding": [{"code": "summary-of-findings", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of Findings"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Composition", "display": "Summary of Findings - QUARTET USA Trial", "reference": "Composition/397488"}], "title": "Summary of Findings"}, {"code": {"coding": [{"code": "discussion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Discussion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Discussion Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "references", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "References"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "Citation", "display": "Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial. (367878)", "reference": "Citation/367878"}], "title": "References Section"}, {"code": {"coding": [{"code": "competing-interests", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Competing Interests"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Competing Interests Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "acknowledgements", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Acknowledgements"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Acknowledgements Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "appendices", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Appendices"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Appendices Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}]}